Pleuritis and pleural effusion as the initial presentation of systemic lupus erythematous in a 23-year-old woman.

Rheumatol Int

Department of Pediatric, Taipei City Hospital, Renai Branch, Da An District, Taipei 106, Taiwan.

Published: October 2008

Systemic lupus erythematous (SLE) is a chronic inflammatory autoimmune disorder that primary affects women and may affect any organ system. Pleural inflammation is a common feature of SLE; however, as an initial presentation in SLE is rare. The author report the case of a 23-year-old woman with chest pain, dyspnea and without fever for 1 week. On physical examination, fine crackles were heard and vocal fremitus was decreased at the base of the left-side of lung. Patient had no symptoms/signs that can meet the SLE criteria; however, immunological workup showed positive response of ANA-speckle, anti-dsDNA, and anti-ENA in patient serum and pleural fluid. Lupus pleuritis with effusions was confirmed by the above investigation. A 1-month course of oral prednisolone-combined oral methrotreate was beneficial in relieving the pleuritis and pleural effusions.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-008-0598-4DOI Listing

Publication Analysis

Top Keywords

pleuritis pleural
8
initial presentation
8
systemic lupus
8
lupus erythematous
8
23-year-old woman
8
pleural effusion
4
effusion initial
4
presentation systemic
4
erythematous 23-year-old
4
woman systemic
4

Similar Publications

Anti-inflammatory and antinociceptive effects of LQFM275 - A new multi-target drug.

Int Immunopharmacol

December 2024

Laboratory of Pharmacology of Natural and Synthetic Products, Institute of Biological Sciences, Federal University of Goiás, Campus Samambaia, Goiânia, Brazil.

Compound (4-(3,5-di-tert-butyl-4-hydroxybenzylamine)benzenesulfonamide) (LQFM275) was designed and synthesized from darbufelone and sulfanilamide as a new multi-target for the treatment of inflammatory diseases. LQFM275 showed a great range of safe cytotoxicity profile (100-400 μM) evaluated by MTT assay, preventing damage induced by lipopolysaccharide (LPS) in EA.hy926 cell line.

View Article and Find Full Text PDF

Background: Tuberculous pleuritis is the second most common extrapulmonary tuberculosis. Its prompt diagnosis and appropriate management are essential to decrease the morbidity and mortality of affected patients. We aimed to assess whether the serum sestrin 2 and fetuin-A levels can be used to diagnose early pleural involvement in patients with pulmonary tuberculosis.

View Article and Find Full Text PDF

Although Aristolochia plants remain controversial due to their toxicity, this group of perianth-bearing plants, which includes the medicinal species Aristolochia esperanzae, is among the most relevant from an ethnobotanical perspective. All parts of A. esperanzae are used in popular medicine in the form of infusion for the treatment of rheumatism.

View Article and Find Full Text PDF

Plasma ferritin, C-reactive protein, and adenosine deaminase levels in tuberculous lymphadenitis and pleuritis and their role in monitoring treatment response.

BMC Infect Dis

December 2024

Center for International Health, Department of Global Public Health and Primary Care, University of Bergen, P.O box 7804, N-5020, Bergen, Norway.

Article Synopsis
  • - The study evaluated plasma levels of ferritin, C-reactive protein (CRP), and adenosine deaminase (ADA) as biomarkers for monitoring treatment response in patients with extrapulmonary tuberculosis (EPTB), specifically those with TB lymphadenitis and TB pleuritis.
  • - Measurements were taken from 92 patients at the beginning of treatment, and again at 2 and 6 months, showing that elevated baseline levels of all three biomarkers significantly decreased after treatment.
  • - Results indicated that a combination of the three biomarkers could predict treatment response with high accuracy, achieving 83% at 2 months and 100% at 6 months, highlighting their potential as indicators of treatment effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!